Cited 33 times in
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김연윤 | - |
dc.date.accessioned | 2021-04-29T17:29:34Z | - |
dc.date.available | 2021-04-29T17:29:34Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182366 | - |
dc.description.abstract | Background: Sarcopenia has been underscored as a significant predictor of poor prognosis in cancer patients undergoing immunotherapy with programmed death-1 (PD-1) inhibitors. We aimed to investigate the prognostic significance of computed tomography (CT)-determined sarcopenia in patients with microsatellite-stable (MSS) gastric cancer (GC) treated with PD-1 inhibitors. Methods: We retrospectively assessed patients with MSS GC who had been treated with PD-1 inhibitors from March 2016 to June 2019. Pre-treatment sarcopenic status was determined by analyzing L3 skeletal muscle index with abdominal CT. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and the differences in survival probability according to sarcopenic status were compared using the log-rank test. Cox proportional hazards regression analyses were performed to identify predictors of PFS and OS. Results: Of 149 patients with MSS GC (mean age, 57.0 ± 12.3 years; 93 men), 79 (53.0%) had sarcopenia. Patients with sarcopenia had significantly shorter PFS than patients without sarcopenia (median, 1.4 months vs. 2.6 months; P = 0.026). Sarcopenia was independently associated with shorter PFS (adjusted hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.10-2.93; P = 0.020). Patients with sarcopenia had shorter OS than patients without sarcopenia (median, 3.6 months vs. 4.9 months; P = 0.052), but sarcopenia itself was not a significant prognostic factor for OS (adjusted HR, 1.01; 95% CI, 0.58-1.75; P = 0.974). Conclusions: CT-determined sarcopenia is an independent prognostic factor for PFS in patients with MSS GC treated with PD-1 inhibitors. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer-Verlag Tokyo | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiology (영상의학교실) | - |
dc.contributor.googleauthor | Yeun-Yoon Kim | - |
dc.contributor.googleauthor | Jeeyun Lee | - |
dc.contributor.googleauthor | Woo Kyoung Jeong | - |
dc.contributor.googleauthor | Seung Tae Kim | - |
dc.contributor.googleauthor | Jae-Hun Kim | - |
dc.contributor.googleauthor | Jung Yong Hong | - |
dc.contributor.googleauthor | Won Ki Kang | - |
dc.contributor.googleauthor | Kyoung-Mee Kim | - |
dc.contributor.googleauthor | Insuk Sohn | - |
dc.contributor.googleauthor | Dongil Choi | - |
dc.identifier.doi | 10.1007/s10120-020-01124-x | - |
dc.contributor.localId | A04902 | - |
dc.relation.journalcode | J00916 | - |
dc.identifier.eissn | 1436-3305 | - |
dc.identifier.pmid | 32970267 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10120-020-01124-x | - |
dc.subject.keyword | Gastric cancer | - |
dc.subject.keyword | Nivolumab | - |
dc.subject.keyword | Pembrolizumab | - |
dc.subject.keyword | Sarcopenia | - |
dc.contributor.alternativeName | Kim, Yeun-Yoon | - |
dc.contributor.affiliatedAuthor | 김연윤 | - |
dc.citation.volume | 24 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 457 | - |
dc.citation.endPage | 466 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, Vol.24(2) : 457-466, 2021-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.